Navigation Links
Chemo With Herceptin May Be Best for Some Breast Cancers
Date:12/12/2009

Taking the drug during chemotherapy, rather than after, improves survival, study finds

SATURDAY, Dec. 12 (HealthDay News) -- New research suggests that certain breast cancer patients who take the drug Herceptin during chemotherapy, instead of taking it afterward, fare better, leading one of the study authors to say patients should routinely take the drug with chemo.

The patients at issue are those with HER2-positive breast cancer, which accounts for 20 percent to 25 percent of all cases of the disease.

Researchers looked at the outcomes for hundreds of women who underwent different treatment regimens. Their findings were to be released at the San Antonio Breast Cancer Symposium, sponsored by the Cancer Therapy & Research Center of the University of Texas, the American Association for Cancer Research and Baylor College of Medicine.

The study found that patients who used Herceptin (also known by the generic name trastuzumab) and chemotherapy together were 25 percent less likely to experience a cancer recurrence or death than those who used the drug after chemotherapy.

"The results of this trial have been eagerly awaited in the U.S. and in many nations as this is the only trial developed to define the optimal way to incorporate Herceptin in the context of adjuvant chemotherapy," Dr. Edith Perez, a breast cancer researcher at the Mayo Clinic in Jacksonville, Fla., said in a news release. "This could mean that up to 10,000 women around the world each year may have a better outcome if Herceptin is used along with chemotherapy. Given that, I believe this study will lead to a global re-evaluation of how Herceptin is used."

More information

Learn more about breast cancer from U.S. National Library of Medicine.



-- Randy Dotinga



SOURCE: Mayo Clinic, news release, Dec. 12, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Definitive study confirms chemo benefit in postmenopausal breast cancer
2. Adding Chemo to Tamoxifen Helps Some Breast Cancer Patients
3. Criteria based on CT imaging after chemotherapy may help predict survival
4. Long-Term Problems Linked to Testicular Cancer Chemo
5. Insomnia prevalent among cancer patients who receive chemotherapy
6. Green tea shows promise as chemoprevention agent for oral cancer, M. D. Anderson study finds
7. Chemo-radiation before prostate removal may prevent cancer recurrence
8. Study of concurrent radiotherapy, chemotherapy shows promise in small cell lung cancer
9. Adding Chemo Helps Head, Neck Cancer Patients
10. Supervised Exercise May Relieve Fatigue During Chemotherapy
11. New chemo cocktail blocks breast cancer like a strong fence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... NJ (PRWEB) , ... December 08, 2016 , ... CURE ... cancer centers and advocacy groups, has aligned with Upstage Lung Cancer in efforts to ... making the announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
(Date:12/8/2016)... ... ... STAT courier is pleased to announce that due to customer demand, as ... their presence in Dallas. One of the most exciting parts for STAT is that ... Dallas and Forth Worth market. STAT takes pride in treating their employees with integrity ...
(Date:12/8/2016)... California (PRWEB) , ... December 08, 2016 , ... ... has raised an $18M Series B led by Canvas Ventures . Other investors ... capital to scale its mobile platform to serve more consumers who are managing ...
(Date:12/8/2016)... ... 2016 , ... Peter Zipp Insurance, an Arizona-based insurance and ... Phoenix metropolitan region, is announcing a charity event to provide support and fund-raising ... Connection is to promote community awareness of the ongoing needs of at-risk youth ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Conn. , Dec. 8, 2016  Boehringer Ingelheim ... 2017 Corporate Equality Index (CEI). This is the ninth ... has been designated as a Best Place to Work ... Foundation, the CEI is a national benchmarking report on ... lesbian, gay, bisexual and transgender (LGBT) employees. ...
(Date:12/8/2016)... Noom, Inc., the leader in mobile health ... only when their members achieve real health outcomes. The ... which typically charges for arbitrary enrollment, participation and engagement ... The company,s ... the empathy of live human coaches to change the ...
(Date:12/8/2016)... CANTEL MEDICAL CORP. (NYSE: CMD ) ... per diluted share, on a 22.1% increase in sales to ... 2016. This compares with net income of $14,254,000, or $0.34 ... quarter ended October 31, 2015. Non-GAAP net ... 2016 to $21,323,000, or $0.51 per diluted share, compared with ...
Breaking Medicine Technology: